conducted a meta-analysis of multiple phase III clinical trials in EC; subgroup analyses suggested significant OS advantage in PD-L1 tumor-positive score (TPS) ≥ 10% groups and obviously longer PFS in the PD-L1 combined positive score (CPS) ≥ 10 groups (35). Here, CD274 is linked to neoplasm.